Lymphoma

Diffuse Large B-Cell

Systemic Treatment with Curative Intent

Previously Treated

Untreated

>1 Relapse

Failure After CAR-T

None at this time

VAR0174
Leveraging Mindsets to Improve Health & Wellbeing in Patients with Cancer
PI: Crum
Sponsor: Stanford University

LYMNH0169
Phase I
Open-label Dose-Escalation & Expansion Study of the Bx优质 Kinase-Targeted Protein-Degradation (BGP-16673 in B-Cell Malignancies
PI: Advani
Sponsor: BeiGene, Ltd.

LYMNH0171
Phase III
Glotifamab (RO7082859) in Combo w/ Polatuzumab, Vedotin plus Rituximab, Cyclophosphamide, Doxorubicin & Prednisone (POLA-R-CHP) vs POLA-R-CHP in Previously Untreated Large B-Cell Lymphoma
PI: Advani
Sponsor: F. Hoffmann-La Roche Ltd.

LYMNH0168
Phase II Study
Evaluating the Safety and Efficacy of Glotifamab in Combo w/ Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vinristine and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Untreated Diffuse Large B-Cell Lymphoma
PI: Advani
Sponsor: F. Hoffmann-La Roche Ltd.

ECOG-ACRIN S1918
Phase III
R-MINICOMP +/- CC-486 (Oral Azacitidine) in Patients 75 years or Older in Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade III Folicular Lymphoma, Transformed Lymphoma, and High Grade B-Cell Lymphomas w/ MYC and BCL2 and/or BCL6 Rearrangements
PI: Advani
Sponsor: ECOG-ACRIN

LYMNH0173
Randomized Open-Label Multicenter Global Phase II Trial to Evaluate the Efficacy & Safety of Epcoritamab (GEN3013; DuoBody-CD20xCD20) as Monotherapy or In Combination w/ Lenalidomide as First-Line Therapy for Anthracycline-Ineligible Subjects With Diffuse Large B-cell Lymphoma
PI: Advani
Sponsor: Genmab

KEY

Pending
Open for Enrollment
Observational Study
Optional Path
Trial Posting
Enrollment on Hold
Extension Study
Immunotherapy

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu